Exact Mass: 479.4008

Exact Mass Matches: 479.4008

Found 115 metabolites which its exact mass value is equals to given mass value 479.4008, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

(13Z,16Z)-Docosadienoylcarnitine

3-[(13Z,16Z)-Docosa-13,16-dienoyloxy]-4-(trimethylammonio)butanoic acid

C29H53NO4 (479.3974)


(13Z,16Z)-Docosadienoylcarnitine is an acylcarnitine. More specifically, it is an (13Z)-docosa-13,16-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (13Z,16Z)-Docosadienoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (13Z,16Z)-Docosadienoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

10-(3,4-Dimethyl-5-pentylfuran-2-yl)decanoylcarnitine

3-{[10-(3,4-dimethyl-5-pentylfuran-2-yl)decanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C28H49NO5 (479.3611)


10-(3,4-dimethyl-5-pentylfuran-2-yl)decanoylcarnitine is an acylcarnitine. More specifically, it is an 10-(3,4-dimethyl-5-pentylfuran-2-yl)decanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-(3,4-dimethyl-5-pentylfuran-2-yl)decanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 10-(3,4-dimethyl-5-pentylfuran-2-yl)decanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

11-(5-Butyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine

3-{[11-(5-butyl-3,4-dimethylfuran-2-yl)undecanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C28H49NO5 (479.3611)


11-(5-butyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-(5-butyl-3,4-dimethylfuran-2-yl)undecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-(5-butyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-(5-butyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

12-(3,4-Dimethyl-5-propylfuran-2-yl)dodecanoylcarnitine

3-{[12-(3,4-dimethyl-5-propylfuran-2-yl)dodecanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C28H49NO5 (479.3611)


12-(3,4-dimethyl-5-propylfuran-2-yl)dodecanoylcarnitine is an acylcarnitine. More specifically, it is an 12-(3,4-dimethyl-5-propylfuran-2-yl)dodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 12-(3,4-dimethyl-5-propylfuran-2-yl)dodecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 12-(3,4-dimethyl-5-propylfuran-2-yl)dodecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

13-(3-Methyl-5-propylfuran-2-yl)tridecanoylcarnitine

3-{[13-(3-methyl-5-propylfuran-2-yl)tridecanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C28H49NO5 (479.3611)


13-(3-methyl-5-propylfuran-2-yl)tridecanoylcarnitine is an acylcarnitine. More specifically, it is an 13-(3-methyl-5-propylfuran-2-yl)tridecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 13-(3-methyl-5-propylfuran-2-yl)tridecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 13-(3-methyl-5-propylfuran-2-yl)tridecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-(5-Hexyl-3,4-dimethylfuran-2-yl)nonanoylcarnitine

3-{[9-(5-hexyl-3,4-dimethylfuran-2-yl)nonanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C28H49NO5 (479.3611)


9-(5-Hexyl-3,4-dimethylfuran-2-yl)nonanoylcarnitine is an acylcarnitine. More specifically, it is an 9-(5-hexyl-3,4-dimethylfuran-2-yl)nonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-(5-Hexyl-3,4-dimethylfuran-2-yl)nonanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-(5-Hexyl-3,4-dimethylfuran-2-yl)nonanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

11-(3-Methyl-5-pentylfuran-2-yl)undecanoylcarnitine

3-{[11-(3-methyl-5-pentylfuran-2-yl)undecanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C28H49NO5 (479.3611)


11-(3-Methyl-5-pentylfuran-2-yl)undecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-(3-methyl-5-pentylfuran-2-yl)undecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-(3-Methyl-5-pentylfuran-2-yl)undecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-(3-Methyl-5-pentylfuran-2-yl)undecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Nervonoyl Isoleucine

3-methyl-2-(tetracos-15-enamido)pentanoic acid

C30H57NO3 (479.4338)


N-nervonoyl isoleucine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Nervonic acid amide of Isoleucine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Nervonoyl Isoleucine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Nervonoyl Isoleucine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Nervonoyl Leucine

4-methyl-2-(tetracos-15-enamido)pentanoic acid

C30H57NO3 (479.4338)


N-nervonoyl leucine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Nervonic acid amide of Leucine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Nervonoyl Leucine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Nervonoyl Leucine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   
   

N-palmitoyl-2-amino-1,3-dihydroxyoctadeca-4,8-diene

N-palmitoyl-2-amino-1,3-dihydroxyoctadeca-4,8-diene

C30H57NO3 (479.4338)


   

Cer(d14:2(4E,6E)/16:0)

N-(hexadecanoyl)-4E,6E-tetradecasphingadienine

C30H57NO3 (479.4338)


   

CAR 22:2

13-cis,16-cis-docosadienoylcarnitine;3-[(13Z,16Z)-docosa-13,16-dienoyloxy]-4-(trimethylammonio)butanoate

C29H53NO4 (479.3974)


   

Cer[NS]

N-(hexadecanoyl)-4E,6E-tetradecasphingadienine

C30H57NO3 (479.4338)


   

Docosyltrimethylammonium methyl sulfate

Docosyltrimethylammonium methyl sulfate

C26H57NO4S (479.4008)


   

benzyldocosyldimethylammonium chloride

benzyldocosyldimethylammonium chloride

C31H58ClN (479.4258)


   

(6Z,9Z,12Z,15Z)-3-hydroxy-2-[(2Z,5Z,8Z,11Z)-tetradeca-2,5,8,11-tetraen-1-yl]octadeca-6,9,12,15-tetraenoate

(6Z,9Z,12Z,15Z)-3-hydroxy-2-[(2Z,5Z,8Z,11Z)-tetradeca-2,5,8,11-tetraen-1-yl]octadeca-6,9,12,15-tetraenoate

C32H47O3- (479.3525)


   

13-(3-Methyl-5-propylfuran-2-yl)tridecanoylcarnitine

13-(3-Methyl-5-propylfuran-2-yl)tridecanoylcarnitine

C28H49NO5 (479.3611)


   

9-(5-Hexyl-3,4-dimethylfuran-2-yl)nonanoylcarnitine

9-(5-Hexyl-3,4-dimethylfuran-2-yl)nonanoylcarnitine

C28H49NO5 (479.3611)


   

11-(3-Methyl-5-pentylfuran-2-yl)undecanoylcarnitine

11-(3-Methyl-5-pentylfuran-2-yl)undecanoylcarnitine

C28H49NO5 (479.3611)


   

10-(3,4-Dimethyl-5-pentylfuran-2-yl)decanoylcarnitine

10-(3,4-Dimethyl-5-pentylfuran-2-yl)decanoylcarnitine

C28H49NO5 (479.3611)


   

11-(5-Butyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine

11-(5-Butyl-3,4-dimethylfuran-2-yl)undecanoylcarnitine

C28H49NO5 (479.3611)


   

12-(3,4-Dimethyl-5-propylfuran-2-yl)dodecanoylcarnitine

12-(3,4-Dimethyl-5-propylfuran-2-yl)dodecanoylcarnitine

C28H49NO5 (479.3611)


   

N-Nervonoyl Leucine

N-Nervonoyl Leucine

C30H57NO3 (479.4338)


   

N-Nervonoyl Isoleucine

N-Nervonoyl Isoleucine

C30H57NO3 (479.4338)


   

N-[(2S,3R,4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadecanamide

N-[(2S,3R,4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadecanamide

C30H57NO3 (479.4338)


   

NAGly 13:1/13:1

NAGly 13:1/13:1

C28H49NO5 (479.3611)


   

NAGly 16:2/10:0

NAGly 16:2/10:0

C28H49NO5 (479.3611)


   

NAGly 10:0/16:2

NAGly 10:0/16:2

C28H49NO5 (479.3611)


   

N-[(4E,8E)-1,3-dihydroxyhexacosa-4,8-dien-2-yl]butanamide

N-[(4E,8E)-1,3-dihydroxyhexacosa-4,8-dien-2-yl]butanamide

C30H57NO3 (479.4338)


   

(Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]henicos-11-enamide

(Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]henicos-11-enamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxyheptacosa-4,8-dien-2-yl]propanamide

N-[(4E,8E)-1,3-dihydroxyheptacosa-4,8-dien-2-yl]propanamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxytricosa-4,8-dien-2-yl]heptanamide

N-[(4E,8E)-1,3-dihydroxytricosa-4,8-dien-2-yl]heptanamide

C30H57NO3 (479.4338)


   

(13Z,16Z)-N-(1,3-dihydroxyoctan-2-yl)docosa-13,16-dienamide

(13Z,16Z)-N-(1,3-dihydroxyoctan-2-yl)docosa-13,16-dienamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxyoctacosa-4,8-dien-2-yl]acetamide

N-[(4E,8E)-1,3-dihydroxyoctacosa-4,8-dien-2-yl]acetamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxydocosa-4,8-dien-2-yl]octanamide

N-[(4E,8E)-1,3-dihydroxydocosa-4,8-dien-2-yl]octanamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxypentacosa-4,8-dien-2-yl]pentanamide

N-[(4E,8E)-1,3-dihydroxypentacosa-4,8-dien-2-yl]pentanamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxyhenicosa-4,8-dien-2-yl]nonanamide

N-[(4E,8E)-1,3-dihydroxyhenicosa-4,8-dien-2-yl]nonanamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxytetracosa-4,8-dien-2-yl]hexanamide

N-[(4E,8E)-1,3-dihydroxytetracosa-4,8-dien-2-yl]hexanamide

C30H57NO3 (479.4338)


   

(11Z,14Z)-N-(1,3-dihydroxynonan-2-yl)henicosa-11,14-dienamide

(11Z,14Z)-N-(1,3-dihydroxynonan-2-yl)henicosa-11,14-dienamide

C30H57NO3 (479.4338)


   

(Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]docos-13-enamide

(Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]docos-13-enamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxynonadeca-4,8-dien-2-yl]undecanamide

N-[(4E,8E)-1,3-dihydroxynonadeca-4,8-dien-2-yl]undecanamide

C30H57NO3 (479.4338)


   

(Z)-N-[(E)-1,3-dihydroxyundec-4-en-2-yl]nonadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxyundec-4-en-2-yl]nonadec-9-enamide

C30H57NO3 (479.4338)


   

(9Z,12Z)-N-(1,3-dihydroxydodecan-2-yl)octadeca-9,12-dienamide

(9Z,12Z)-N-(1,3-dihydroxydodecan-2-yl)octadeca-9,12-dienamide

C30H57NO3 (479.4338)


   

(Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]octadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]octadec-9-enamide

C30H57NO3 (479.4338)


   

(Z)-N-[(E)-1,3-dihydroxyheptadec-4-en-2-yl]tridec-9-enamide

(Z)-N-[(E)-1,3-dihydroxyheptadec-4-en-2-yl]tridec-9-enamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]octadecanamide

N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]octadecanamide

C30H57NO3 (479.4338)


   

(Z)-N-[(E)-1,3-dihydroxytridec-4-en-2-yl]heptadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxytridec-4-en-2-yl]heptadec-9-enamide

C30H57NO3 (479.4338)


   

(Z)-N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]hexadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]hexadec-9-enamide

C30H57NO3 (479.4338)


   

(9Z,12Z)-N-(1,3-dihydroxytetradecan-2-yl)hexadeca-9,12-dienamide

(9Z,12Z)-N-(1,3-dihydroxytetradecan-2-yl)hexadeca-9,12-dienamide

C30H57NO3 (479.4338)


   

(11Z,14Z)-N-(1,3-dihydroxydecan-2-yl)icosa-11,14-dienamide

(11Z,14Z)-N-(1,3-dihydroxydecan-2-yl)icosa-11,14-dienamide

C30H57NO3 (479.4338)


   

(9Z,12Z)-N-(1,3-dihydroxytridecan-2-yl)heptadeca-9,12-dienamide

(9Z,12Z)-N-(1,3-dihydroxytridecan-2-yl)heptadeca-9,12-dienamide

C30H57NO3 (479.4338)


   

(9Z,12Z)-N-(1,3-dihydroxyundecan-2-yl)nonadeca-9,12-dienamide

(9Z,12Z)-N-(1,3-dihydroxyundecan-2-yl)nonadeca-9,12-dienamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]heptadecanamide

N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]heptadecanamide

C30H57NO3 (479.4338)


   

(Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]icos-11-enamide

(Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]icos-11-enamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxyicosa-4,8-dien-2-yl]decanamide

N-[(4E,8E)-1,3-dihydroxyicosa-4,8-dien-2-yl]decanamide

C30H57NO3 (479.4338)


   

Cer-NDS d30:2

Cer-NDS d30:2

C30H57NO3 (479.4338)


   

(Z)-N-[(8E,12E)-1,3,4-trihydroxytetradeca-8,12-dien-2-yl]pentadec-9-enamide

(Z)-N-[(8E,12E)-1,3,4-trihydroxytetradeca-8,12-dien-2-yl]pentadec-9-enamide

C29H53NO4 (479.3974)


   

(Z)-N-[(8E,12E)-1,3,4-trihydroxypentadeca-8,12-dien-2-yl]tetradec-9-enamide

(Z)-N-[(8E,12E)-1,3,4-trihydroxypentadeca-8,12-dien-2-yl]tetradec-9-enamide

C29H53NO4 (479.3974)


   

(Z)-N-[(E)-1,3-dihydroxyhexadec-4-en-2-yl]tetradec-9-enamide

(Z)-N-[(E)-1,3-dihydroxyhexadec-4-en-2-yl]tetradec-9-enamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]pentadecanamide

N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]pentadecanamide

C30H57NO3 (479.4338)


   

(Z)-N-[(8E,12E)-1,3,4-trihydroxyheptadeca-8,12-dien-2-yl]dodec-5-enamide

(Z)-N-[(8E,12E)-1,3,4-trihydroxyheptadeca-8,12-dien-2-yl]dodec-5-enamide

C29H53NO4 (479.3974)


   

(Z)-N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]pentadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxypentadec-4-en-2-yl]pentadec-9-enamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]tridecanamide

N-[(4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]tridecanamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]dodecanamide

N-[(4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]dodecanamide

C30H57NO3 (479.4338)


   

(Z)-N-[(8E,12E)-1,3,4-trihydroxyhexadeca-8,12-dien-2-yl]tridec-8-enamide

(Z)-N-[(8E,12E)-1,3,4-trihydroxyhexadeca-8,12-dien-2-yl]tridec-8-enamide

C29H53NO4 (479.3974)


   

N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadecanamide

N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadecanamide

C30H57NO3 (479.4338)


   

N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]tetradecanamide

N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]tetradecanamide

C30H57NO3 (479.4338)


   

Cer 14:3;2O/15:0;(2OH)

Cer 14:3;2O/15:0;(2OH)

C29H53NO4 (479.3974)


   

Cer 17:3;2O/12:0;(2OH)

Cer 17:3;2O/12:0;(2OH)

C29H53NO4 (479.3974)


   

Cer 15:2;2O/14:1;(2OH)

Cer 15:2;2O/14:1;(2OH)

C29H53NO4 (479.3974)


   

Cer 15:2;2O/14:1;(3OH)

Cer 15:2;2O/14:1;(3OH)

C29H53NO4 (479.3974)


   

Cer 17:3;2O/12:0;(3OH)

Cer 17:3;2O/12:0;(3OH)

C29H53NO4 (479.3974)


   

Cer 14:2;2O/15:1;(3OH)

Cer 14:2;2O/15:1;(3OH)

C29H53NO4 (479.3974)


   

Cer 14:2;2O/15:1;(2OH)

Cer 14:2;2O/15:1;(2OH)

C29H53NO4 (479.3974)


   

Cer 15:3;2O/14:0;(3OH)

Cer 15:3;2O/14:0;(3OH)

C29H53NO4 (479.3974)


   

Cer 14:3;2O/15:0;(3OH)

Cer 14:3;2O/15:0;(3OH)

C29H53NO4 (479.3974)


   

Cer 16:2;2O/13:1;(2OH)

Cer 16:2;2O/13:1;(2OH)

C29H53NO4 (479.3974)


   

Cer 16:2;2O/13:1;(3OH)

Cer 16:2;2O/13:1;(3OH)

C29H53NO4 (479.3974)


   

Cer 16:3;2O/13:0;(2OH)

Cer 16:3;2O/13:0;(2OH)

C29H53NO4 (479.3974)


   

Cer 17:2;2O/12:1;(2OH)

Cer 17:2;2O/12:1;(2OH)

C29H53NO4 (479.3974)


   

Cer 15:3;2O/14:0;(2OH)

Cer 15:3;2O/14:0;(2OH)

C29H53NO4 (479.3974)


   

Cer 17:2;2O/12:1;(3OH)

Cer 17:2;2O/12:1;(3OH)

C29H53NO4 (479.3974)


   

Cer 16:3;2O/13:0;(3OH)

Cer 16:3;2O/13:0;(3OH)

C29H53NO4 (479.3974)


   

(Z)-N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]hexadec-7-enamide

(Z)-N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]hexadec-7-enamide

C30H57NO3 (479.4338)


   

(Z)-N-[(E)-1,3-dihydroxyoctadec-4-en-2-yl]dodec-5-enamide

(Z)-N-[(E)-1,3-dihydroxyoctadec-4-en-2-yl]dodec-5-enamide

C30H57NO3 (479.4338)


   

(Z)-N-[(E)-1,3-dihydroxyheptadec-4-en-2-yl]tridec-8-enamide

(Z)-N-[(E)-1,3-dihydroxyheptadec-4-en-2-yl]tridec-8-enamide

C30H57NO3 (479.4338)


   

N-[(2S,3R,4E,14E)-1,3-dihydroxyoctadeca-4,14-dien-2-yl]dodecanamide

N-[(2S,3R,4E,14E)-1,3-dihydroxyoctadeca-4,14-dien-2-yl]dodecanamide

C30H57NO3 (479.4338)


   

(E)-N-[(E,2S,3R)-1,3-dihydroxytetradec-8-en-2-yl]hexadec-9-enamide

(E)-N-[(E,2S,3R)-1,3-dihydroxytetradec-8-en-2-yl]hexadec-9-enamide

C30H57NO3 (479.4338)


   

N-[(2S,3R,4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]pentadecanamide

N-[(2S,3R,4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]pentadecanamide

C30H57NO3 (479.4338)


   

(E)-N-[(E,2S,3R)-1,3-dihydroxytetradec-4-en-2-yl]hexadec-9-enamide

(E)-N-[(E,2S,3R)-1,3-dihydroxytetradec-4-en-2-yl]hexadec-9-enamide

C30H57NO3 (479.4338)


   

N-[(2S,3R,4E,6E)-1,3-dihydroxyhexadeca-4,6-dien-2-yl]tetradecanamide

N-[(2S,3R,4E,6E)-1,3-dihydroxyhexadeca-4,6-dien-2-yl]tetradecanamide

C30H57NO3 (479.4338)


   

N-[(2S,3R,4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]tridecanamide

N-[(2S,3R,4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]tridecanamide

C30H57NO3 (479.4338)


   

N-[(2S,3R,4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]dodecanamide

N-[(2S,3R,4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]dodecanamide

C30H57NO3 (479.4338)


   

N-[(2S,3R,4E,6E)-1,3-dihydroxypentadeca-4,6-dien-2-yl]pentadecanamide

N-[(2S,3R,4E,6E)-1,3-dihydroxypentadeca-4,6-dien-2-yl]pentadecanamide

C30H57NO3 (479.4338)


   

N-[(2S,3R,4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]tetradecanamide

N-[(2S,3R,4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]tetradecanamide

C30H57NO3 (479.4338)


   

N-[(2S,3R,4E,8E)-1,3-dihydroxyicosa-4,8-dien-2-yl]decanamide

N-[(2S,3R,4E,8E)-1,3-dihydroxyicosa-4,8-dien-2-yl]decanamide

C30H57NO3 (479.4338)


   

(13Z,16Z)-docosadienoylcarnitine

(13Z,16Z)-docosadienoylcarnitine

C29H53NO4 (479.3974)


An O-acylcarnitine having (13Z,16Z)-docosadienoyl as the acyl substituent.

   

NA-2AAA 22:2(13Z,16Z)

NA-2AAA 22:2(13Z,16Z)

C28H49NO5 (479.3611)


   
   

Cer 14:1;O2/16:1

Cer 14:1;O2/16:1

C30H57NO3 (479.4338)


   

Cer 14:2;O2/16:0

Cer 14:2;O2/16:0

C30H57NO3 (479.4338)


   

Cer 15:1;O2/15:1

Cer 15:1;O2/15:1

C30H57NO3 (479.4338)


   

Cer 15:2;O2/15:0

Cer 15:2;O2/15:0

C30H57NO3 (479.4338)


   

Cer 16:1;O2/14:1

Cer 16:1;O2/14:1

C30H57NO3 (479.4338)


   

Cer 16:2;O2/14:0

Cer 16:2;O2/14:0

C30H57NO3 (479.4338)


   

Cer 17:2;O2/13:0

Cer 17:2;O2/13:0

C30H57NO3 (479.4338)


   

Cer 18:1;O2/12:1

Cer 18:1;O2/12:1

C30H57NO3 (479.4338)


   

Cer 18:2;O2/12:0

Cer 18:2;O2/12:0

C30H57NO3 (479.4338)


   

Cer 19:2;O2/11:0

Cer 19:2;O2/11:0

C30H57NO3 (479.4338)


   

Cer 20:2;O2/10:0

Cer 20:2;O2/10:0

C30H57NO3 (479.4338)


   

Cer 14:0;O2/16:2

Cer 14:0;O2/16:2

C30H57NO3 (479.4338)


   

ST 26:0;O3;Gly

ST 26:0;O3;Gly

C28H49NO5 (479.3611)


   

n-(1,3-dihydroxytetradeca-4,8-dien-2-yl)hexadecanimidic acid

n-(1,3-dihydroxytetradeca-4,8-dien-2-yl)hexadecanimidic acid

C30H57NO3 (479.4338)


   

n-[(2s,3r,4e,8e)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadecanimidic acid

n-[(2s,3r,4e,8e)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadecanimidic acid

C30H57NO3 (479.4338)